PT-141 (bremelanotide) is a synthetic peptide analog of alpha-melanocyte-stimulating hormone studied for its association with sexual wellness pathways. It is commonly explored in provider-directed sexual health and wellness programs and should be evaluated based on the individual patient, treatment objective, and applicable prescribing information.
What It Is Used For
PT-141 is commonly considered in provider-directed programs focused on the following areas of interest:
Sexual Wellness — Often considered in provider-directed programs focused on sexual health and wellness objectives.
Melanocortin Pathway Support — May be explored within programs designed to support melanocortin-related wellness pathways.
Hormonal Health — May be considered for patients whose goals include hormonal and sexual-wellness support.
PT-141 should be evaluated against applicable prescribing information. Information provided by ALML is intended for healthcare professionals and does not replace independent clinical judgment.
How It Works
PT-141 (bremelanotide) is a synthetic peptide analog of alpha-melanocyte-stimulating hormone that acts within the melanocortin system, distinct from phosphodiesterase-based pathways. Areas of biological activity include:
Areas being studied include:
Melanocortin Receptor Activity — PT-141 has been studied for its interaction with melanocortin receptors, which are involved in multiple physiological pathways.
Central Nervous System Pathways — Research has investigated potential effects on central nervous system pathways associated with sexual wellness, distinct from peripheral vascular mechanisms.
Neuroendocrine Signaling — Preclinical research has explored potential effects on neuroendocrine signaling pathways relevant to sexual health.
Hormonal Pathway Interactions — Research has explored potential interactions with hormonal and melanocortin-related pathways.
Clinical use of PT-141 varies by patient-specific factors and applicable prescribing information. The treating healthcare professional remains responsible for all clinical decision-making. This information is educational and does not establish clinical efficacy for any specific use.
Clinical Information
Healthcare professionals should independently evaluate the available evidence, patient-specific factors, potential risks, and applicable regulatory requirements before considering PT-141 for a patient.
Include these considerations:
Patient-Specific Assessment Required — Providers should consider the patient's medical history, current medications, allergies, pregnancy or breastfeeding status, and other relevant clinical factors before use.
Use Within Approved and Appropriate Context — PT-141 should be evaluated against applicable prescribing information and used only where clinically appropriate for the individual patient.
Monitor Tolerance and Relevant Clinical Factors — Providers should monitor patient tolerance and relevant clinical factors, including cardiovascular-related factors, throughout the course of use.
Treatment Decisions Remain With the Licensed Healthcare Professional — All treatment, prescribing, and dosing decisions remain solely the responsibility of the appropriately licensed healthcare professional.
ALML provides product and educational information for healthcare professionals. This information is not a substitute for prescribing information, pharmacy labeling, applicable law, or independent clinical judgment.
Available Options
Option 1
Verified formulations and strengths will be updated based on current pharmacy availability.
Dosing & Reconstitution
For provider use only. Calculates reconstitution math — does not select or recommend a patient dose.
Product Dosing Schedule
Provider Inputs
Calculated Outputs
Concentration
—
Medication amount ÷ diluent mL
Volume to Draw
—
Desired dose ÷ concentration
U-100 Syringe Units
—
Volume to draw × 100 — 100 syringe units = 1.00 mL · 1 syringe unit = 0.01 mL
| Low / Starting Dose | 1 mg once daily |
| Standard Dose | 1.5 mg once daily |
| High Dose | 2 mg once daily |
| Frequency | Daily |
| Dose Unit | mg/day |
| Administrations Per Week | 7 |
Dosing information is provided for healthcare-professional reference only when verified. Patient-specific dosing and prescribing decisions remain the responsibility of the treating healthcare professional.
This tool performs reconstitution/administration math only. It does not select, recommend, or validate a patient dose. Dosing decisions are the responsibility of the prescribing healthcare provider.
Ask ALML
Ask ALML may identify PT-141 as a product for a healthcare professional to explore when the described patient goals involve sexual wellness, melanocortin-pathway support, or hormonal health.
The match is informational. Ask ALML is designed to help healthcare professionals navigate the ALML portfolio and identify potentially relevant options for further clinical consideration. It does not diagnose a patient, prescribe treatment, determine medical necessity, or select patient-specific dosing.
Submit an order request or ask about availability. A request is not a guaranteed order — every inquiry goes to ALML staff for manual review and follow-up.
ALML does not guarantee that any specific therapy can be supplied. Availability is confirmed through manual review of each request.